MitoStack
MitoStack is a research-compound blend of SS-31 (elamipretide) and MOTS-c, 25 mg each in a 50 mg vial, studied for mitochondrial function; research protocols typically dose it every other day by subcutaneous injection in insulin units, in 8-week-on / 4-week-off cycles.
Mitochondrial and metabolic research interest — cellular energy, exercise capacity and metabolic-flexibility questions — combining a cardiolipin-targeting peptide with a mitochondrial-derived peptide.
SS-31 (elamipretide) is a four-amino-acid Szeto-Schiller peptide that concentrates in the inner mitochondrial membrane and binds cardiolipin, where research describes stabilized electron-transport-chain supercomplexes, improved ATP production and reduced reactive-oxygen-species leak. MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA that activates AMPK and, under metabolic stress, translocates to the nucleus to regulate stress-response genes; animal studies report improved insulin sensitivity and exercise capacity. The two are paired on the rationale that one acts on the membrane machinery and the other on metabolic signaling.
Elamipretide has been through human trials (including Barth syndrome); MOTS-c evidence is animal and early human. Neither is FDA-approved for these uses; the blend is handled as a research compound.
Subcutaneous injection every other day, morning or pre-workout, dosed in units from a 50 mg vial reconstituted with 3 mL of bacteriostatic water. 8 weeks on, 4 weeks off — both components are typically cycled rather than run continuously.
MOTS-c studies report metabolic and exercise-capacity changes over weeks; elamipretide trial endpoints were measured over weeks to months. Human onset data for the blend itself do not exist.
Frequently discussed alongside NAD+ and 5-Amino-1MQ in mitochondrial and metabolic stacks.
- A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome (TAZPOWER)
- Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER
- The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance
Log every dose, count every vial, and verify your batches — free in the goodtides app.
This page is educational reference material about compounds studied in research settings. It is not medical advice, and nothing here is a recommendation to buy, possess, or use any compound. Research findings described are from published literature; individual compounds may not be approved for human use. Talk to a licensed clinician about anything that affects your health.